We can’t show the full text here under this license. Use the link below to read it at the source.
Upper and/or lower gastrointestinal adverse events with glucagon‐like peptide‐1 receptor agonists: I ncidence and consequences
Stomach and intestinal side effects of glucagon-like peptide-1 receptor drugs: how often they occur and their impact
AI simplified
Abstract
Fewer 34% of patients treated with exenatide once weekly reported gastrointestinal adverse events compared to 45% with exenatide twice daily and 41% with liraglutide.
- Nausea was the most common gastrointestinal adverse event across all treatments.
- Fewer patients treated with exenatide once weekly reported upper and lower gastrointestinal events compared to those on liraglutide.
- The incidence of gastrointestinal adverse events was similar between exenatide once weekly and twice daily, with no significant difference.
- More women than men reported gastrointestinal adverse events within each treatment group.
- Gastrointestinal adverse events were typically mild, occurring early in the treatment process.
- Weight loss was greater among patients experiencing gastrointestinal adverse events with exenatide treatments.
AI simplified
Key numbers
34% vs 45%
Gastrointestinal AE Incidence Reduction
Incidence of gastrointestinal AEs in pooled analysis for exenatide once weekly and twice daily.
25% vs 41%
Gastrointestinal AE Incidence with Liraglutide
Incidence of gastrointestinal AEs for exenatide once weekly compared to liraglutide.
−2.7 kg vs −2.0 kg
Weight Loss Difference
Weight loss in patients with and without gastrointestinal AEs for exenatide once weekly.